Analysis of Pediatric Intensive Care Unit Admissions for Crimean–Congo Hemorrhagic Fever in Turkey

Abstract

Objective The aim of this study was to determine the clinical characteristics, course of disease, and outcomes of patients admitted to our pediatric intensive care unit (PICU) for Crimean–Congo hemorrhagic fever (CCHF).

Methods Data of all patients with CCHF who were admitted to PICU during a 3-year period and whose diagnosis was confirmed by serological methods or polymerase chain reaction were retrospectively reviewed. Their presenting characteristics, treatments, and outcomes were extracted from the hospital's electronic database. Disease severity scoring was performed using the severity scoring index and severity grading score system.

Results The data of 22 of 123 patients with suspected CCHF who were admitted to PICU were evaluated. Among them, 68.2% were males and mean age of all patients was 13.4 ± 2.2 years. The average length of stay of 10 patients was >10 days. On average, 3.72 units of platelet suspension per patient was transfused. In the course of the disease, the highest laboratory values were reached on day 3 of admission.

Conclusion Poor CCHF outcome depends on thrombocytopenia severity, prolonged coagulation tests, high-liver enzyme levels, and disseminated intravascular coagulation. Poor outcomes can be avoided by CCHF awareness and preparedness, early diagnosis of the disease, and supportive treatment with appropriate fluid and blood product transfusion. Randomized controlled trials on prophylactic transfusion and ribavirin use are needed.

Keywords

Crimean–Congo hemorrhagic fever - pediatric intensive care unit - Turkey

Note

The study was performed at the Gaziosmanpasa University Health Research and Training Center.

Publikationsverlauf

Eingereicht: 27. Januar 2020

Angenommen: 04. Mai 2020

Artikel online veröffentlicht:
22. Juni 2020

• References

• 1 Leblebicioglu H. Crimean-Congo haemorrhagic fever in Eurasia. Int J Antimicrob Agents 2010; 36 (Suppl. 01) S43-S46
• 2 Bodur H, Akinci E, Ascioglu S, Öngürü P, Uyar Y. Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey. Emerg Infect Dis 2012; 18 (04) 640-642
• 3 Tuygun N, Tanir G, Caglayik DY, Uyar Y, Korukluoglu G, Cenesiz F. Pediatric cases of Crimean-Congo hemorrhagic fever in Turkey. Pediatr Int 2012; 54 (03) 402-406
• 4 Leblebicioglu H, Ozaras R, Irmak H, Sencan I. Crimean-Congo hemorrhagic fever in Turkey: current status and future challenges. Antiviral Res 2016; 126: 21-34
• 5 Ergonul O, Tuncbilek S, Baykam N, Celikbas A, Dokuzoguz B. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis 2006; 193 (07) 941-944
• 6 Sunbul M, Leblebicioglu H, Fletcher TE. , et al. Crimean-Congo haemorrhagic fever and secondary bacteraemia in Turkey. J Infect 2015; 71 (05) 597-599
• 7 Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989; 11 (Suppl. 04) S794-S800
• 8 Bakir M, Engin A, Gozel MG, Elaldi N, Kilickap S, Cinar Z. A new perspective to determine the severity of cases with Crimean-Congo hemorrhagic fever. J Vector Borne Dis 2012; 49 (02) 105-110
• 9 Bakır M, Gözel MG, Köksal I. , et al. Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean-Congo hemorrhagic fever (CCHF). Eur J Clin Microbiol Infect Dis 2015; 34 (02) 325-330
• 10 Bozkurt I, Sunbul M, Yilmaz H, Esen S, Leblebicioglu H, Beeching NJ. Direct healthcare costs for patients hospitalized with Crimean-Congo haemorrhagic fever can be predicted by a clinical illness severity scoring system. Pathog Glob Health 2016; 110 (01) 9-13
• 11 Dokuzoguz B, Celikbas AK, Gök ŞE, Baykam N, Eroglu MN, Ergönül Ö. Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality. Clin Infect Dis 2013; 57 (09) 1270-1274
• 12 Akinci E, Bodur H, Sunbul M, Leblebicioglu H. Prognostic factors, pathophysiology and novel biomarkers in Crimean-Congo hemorrhagic fever. Antiviral Res 2016; 132: 233-243
• 13 WHO, Crimean-Congo haemorrhagic fever. 2016 ; Available at: http://www.who.int/mediacentre/factsheets/fs208/en/
• 14 Karakecili F, Cikman A, Aydin M, Binay UD, Kesik OA, Ozcicek F. Evaluation of epidemiological, clinical, and laboratory characteristics and mortality rate of patients with Crimean-Congo hemorrhagic fever in the northeast region of Turkey. J Vector Borne Dis 2018; 55 (03) 215-221
• 15 Papa A, Bino S, Velo E, Harxhi A, Kota M, Antoniadis A. Cytokine levels in Crimean-Congo hemorrhagic fever. J Clin Virol 2006; 36 (04) 272-276
• 16 Onguru P, Dagdas S, Bodur H. , et al. Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its relation with mortality. J Clin Lab Anal 2010; 24 (03) 163-166
• 17 Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res 2013; 100 (01) 159-189
• 18 Sharifi-Mood B, Mardani M, Keshtkar-Jahromi M, Rahnavardi M, Hatami H, Metanat M. Clinical and epidemiologic features of Crimean-Congo hemorrhagic fever among children and adolescents from southeastern Iran. Pediatr Infect Dis J 2008; 27 (06) 561-563
• 19 Dilber E, Cakir M, Acar EA. , et al. Crimean-Congo haemorrhagic fever among children in north-eastern Turkey. Ann Trop Paediatr 2009; 29 (01) 23-28
• 20 Ergönül O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006; 6 (04) 203-214
• 21 Ergönül O, Celikbaş A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004; 39 (02) 284-287
• 22 Schwarz TF, Nsanze H, Ameen AM. Clinical features of Crimean-Congo haemorrhagic fever in the United Arab Emirates. Infection 1997; 25 (06) 364-367
• 23 Mardani M, Rahnavardi M, Sharifi-Mood B. Current treatment of Crimean-Congo hemorrhagic fever in children. Expert Rev Anti Infect Ther 2010; 8 (08) 911-918
• 24 Oncü S. Crimean-Congo hemorrhagic fever: an overview. Virol Sin 2013; 28 (04) 193-201
• 25 Yilmaz R, Kundak AA, Ozer S, Esmeray H. Successful treatment of severe Crimean-Congo hemorrhagic fever with supportive measures without ribavirin and hypothermia. J Clin Virol 2009; 44 (02) 181-182
• 26 Karti SS, Odabasi Z, Korten V. , et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 2004; 10 (08) 1379-1384
• 27 Tezer H, Sucakli IA, Sayli TR. , et al. Crimean-Congo hemorrhagic fever in children. J Clin Virol 2010; 48 (03) 184-186
• 28 Chandralekha P, Gupta P, Trikha A. The north Indian dengue outbreak 2006: a retrospective analysis of intensive care unit admissions in a tertiary care hospital. Trans R Soc Trop Med Hyg 2008; 102 (02) 143-147
• 29 Squires JE. Indications for platelet transfusion in patients with thrombocytopenia. Blood Transfus/Trasfusione del sangue 2015; 13 (02) 221-226
• 30 Sharma S, Sharma P, Tyler LN. Transfusion of blood and blood products: indications and complications. Am Fam Physician 2011; 83 (06) 719-724
• 31 Slater A, Shann F, Pearson G. ; Paediatric Index of Mortality (PIM) Study Group. PIM2: a revised version of the paediatric index of mortality. Intensive Care Med 2003; 29 (02) 278-285
• 32 Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated pediatric risk of mortality score. Crit Care Med 1996; 24 (05) 743-752
• 33 Mertens M, Schmidt K, Ozkul A, Groschup MH. The impact of Crimean-Congo hemorrhagic fever virus on public health. Antiviral Res 2013; 98 (02) 248-260